Phyton Biotech, a German/North American Plant Cell Fermentation technology company, and AqVida, a German oncology Finished Dosage Formulation (FDF) manufacturer, have received European approval from the European Directorate of Quality Medicines for AqVida's paclitaxel injectable FDF, it was reported yesterday.
According to the strategic partnership agreement with AqVida, Phyton Biotech will be the exclusive supplier of paclitaxel API for AqVida's Taxol generic formulation, which is produced in AqVida's new state-of-the-art injectable manufacturing facility situated in Dassow, Germany. AqVida's ultra-modern robotic manufacturing line, designed for filling cytotoxic injectables, will be used to produce AqVida's generic oncology medicines to treat common types of cancer.
Wolfgang Heinze, chief executive officer (CEO) of AqVida, said, 'We chose to work with Phyton because of the company's superior quality fermentation-produced API, in comparison to naturally extracted or semi-synthetically produced alternatives. Approval of ourpaclitaxel injectable FDF by the European Directorate of Quality Medicines is a major milestone for our company.'
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets
Newbury Pharmaceuticals secures approval for Macitentan in Denmark
Mallinckrodt and Endo to merge in USD6.7bn deal to create pharmaceutical leader
Genomma Lab Internacional announces quarterly dividend
Aveva Drug Delivery systems introduces generic Fentanyl Transdermal Patch in US
Independent Pharmacy Cooperative signs cooperation agreement with Legacy Pharmacy Group
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Newbury Pharmaceuticals secures generic approval for pomalidomide in Denmark
Newbury Pharmaceuticals secures generic approval for Bosutinib in Norway
Guangzhou Fermion Technology partners with Simcere Pharmaceutical